Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Roberts and Ryan Honors the Families of Fallen Patriots on this Year’s National Gold Star Mother’s and Family’s Day

Roberts & Ryan Investments, Inc.

Roberts & Ryan, America’s first Service-Disabled Veteran-Owned Broker Dealer, pauses today to recognize and honor the nation’s Gold Star Mothers and Families who have lost a loved one in military service to our country. Since World War I, the title “Gold Star Family” has been reserved for the families of military members who have died in the line of duty. In 1936, the last Sunday in September was designated “Gold Star Mother’s Day,” and in 2009, “Gold Star Mother’s and Family’s Day,” a day to honor these families and the ultimate sacrifice of their loved ones. Roberts and Ryan extends its warm thoughts and gratitude this Sunday to the more than 470,000 Gold Star Families. With over $1.5 million in committed donations to Veteran’s causes, Roberts and Ryan passionately supports those who have fought to protect our freedoms. Roberts and Ryan actively engages with numerous charities and foundations that serve Veterans and their families, such as the Tunnel to Towers Foundation, Children of Fallen Patriots, Boulder Crest, the Robert Irvine Foundation, and many other world-class organizations. Programs focused on issues arising from PTSD, providing funding for Veterans who have lost their mobility, and offering scholarships for children who have lost an active-duty parent are among the ongoing causes Roberts and Ryan fervently supports. This year on Gold Star Mother’s and Family’s Day, Roberts and Ryan invites us all to consider the sacrifice given in the name of our freedoms and the heroism displayed daily; and extends its deep gratitude to Gold Star Families in honor of soldiers lost. Contact Details Roberts and Ryan Tracy Rosensteel +1 917-887-1227 trosensteel@roberts-ryan.com Company Website https://www.roberts-ryan.com

September 23, 2022 01:00 PM Eastern Daylight Time

How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Unicycive Therapeautics, Inc.

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000 suffer from end-stage renal disease (ESRD). Of these, nearly 500,000 require dialysis to stay alive. In fact, each year, more people die from this silent killer than from breast or prostate cancer. Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients. Uncontrolled phosphorus levels will often cause other complications like heart disease and bone fractures, increasing the risk of hospitalization by up to 38% and the risk of mortality by up to a staggering 102%. Even though there are six Food and Drug Administration (FDA)-approved drugs on the market to treat hyperphosphatemia, 75% of patients with hyperphosphatemia are unable to bring their phosphorus down to target levels Some of the currently available products include Auryxia, produced by Akebia Therapeutics (NASDAQ: AKBA), and Velphoro, from Fresenius Medical Care AG & Co. (NYSE: FMS). As such, it would appear that the medications currently available on the market are unable to fully address the needs of the patient population. One company from California is looking to do its bit to help change that. Will Their New Pill Help Solve This Growing Problem? Unicycive Therapeutics Inc. (NASDAQ: UNCY), a Los Altos, California company, is seeking to develop a solution that is more effective than its competitors. The company is developing a proprietary drug called Renazorb TM which is less than 2 years away from potential FDA approval, that binds and eliminates phosphate in the GI tract. This new drug uses a patented nanoparticle technology that (if approved) Unicycive believes will more effectively reduce phosphorus to target levels. Renazorb TM also offers added convenience to patients because it is swallowed with water instead of having to be chewed. Recently Unicycive commissioned a survey of nephrologists — doctors who specialize in kidney health — and found that their top concerns in managing hyperphosphatemia in their patients was the need for a lower pill burden and better patient compliance. Many people suffering from hyperphosphatemia also have other comorbidities that require taking other pills, creating a high pill burden. This leads to 62% of patients self-reporting non-compliance — patients neglecting to take their medication because they are overwhelmed by the number and size of the pills that they must take and their side effects. The efficiency and smaller size of Renazorb TM pills may reduce the pill burden for these patients by 3 to 4 fold. Accordingly, nephrologists say they would prescribe Renazorb TM (once approved) to 34% of their dialysis patients requiring phosphate binder therapy - this is a market-leading figure indicative of the levels of practitioner confidence in the promise for this new drug. Notably, Unicycive also recently signed an agreement with Lee’s Pharmaceutical (HK) Ltd., a subsidiary of Lee’s Pharmaceutical Holdings Ltd. (OTC: LPCUF), for exclusive distribution rights to Renazorb TM in China and other Asian markets. The worldwide market for hyperphosphatemia drugs sits at over $2 billion (with over $1 bn of that being the U.S. market). It is expected to achieve a 5.3% compound annual growth rate between 2021 and 2028. Unicycive believes that this leaves the field wide open for a drug that will bring real solutions to patients suffering from inadequate and burdensome medicine for a persistent medical problem worldwide. “We were delighted to initiate our pivotal bioequivalence trial of Renazorb (™), which keeps us on track to complete the study around year-end and to file a new drug application in 2023,” said Unicycive CEO Shalaba Gupta. He also said that the agreement with Lee’s Pharmaceutical “underscores the potential for Renazorb (™) as a best-in-class phosphate binder worldwide.” To learn more about the company, visit its website www.unicycive.com. Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Anne Marie Fields - Stern Investor Relations +1 212-362-1200 annemarie.fields@sternir.com Company Website https://unicycive.com/

September 23, 2022 09:11 AM Eastern Daylight Time

Fall Health Checklist from the College of American Pathologists

YourUpdateTV

A video accompanying this announcement is available at: https://youtu.be/ns5Nn7nlbyY Summer is coming to a close, which means it’s the perfect time to take stock of your health and set yourself up for success the rest of the year. The FDA has recently changed their guidelines regarding Covid at-home tests, now advising people to take three tests, instead of the previously recommended two tests. The agency issued the update just ahead of the back-to-school season – an attempt to reduce the risk of infection being missed and to help people from unknowingly spreading the virus. But COVID isn’t the only thing on people’s minds. With fall approaching, cold and flu season isn’t far behind. This time of year can create confusion for people who may not be able to tell the difference between COVID symptoms and cold/flu symptoms. There are also concerns about the spread of Monkeypox and the re-emergence of Polio. During a nationwide media tour on September 15th, Dr. Emily Volk – President of the College of American Pathologists discussed: · Changing FDA guidelines around COVID testing and what you need to know · Navigating flu shots and COVID boosters · Tips for knowing the difference between COVID symptoms and cold/flu symptoms · Additional insights on recent health concerns such as Monkeypox and Polio For more information, visit CDC.GOV or FDA.GOV Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 22, 2022 04:30 PM Eastern Daylight Time

Video

Is Screen Time Affecting Your Eye Health?

YourUpdateTV

A new partnership with the American Optometric Association (AOA), the leading authority on quality eye care and the gaming industry is underway to address the effects of prolonged screen time and its impact on eye health. AOA launched the first-of-its kind Screen Time Alliance with Nerd Street Gamers, a national network of e-sports facilities, events, and content, and Playcrafting, a game development company, to encourage Americans to get their eyes checked offline by a doctor of optometry so they can do more of what they love online. There are more than 227 million Americans who play video games1 and with gaming and screen time on the rise, so is the risk for long-term implications for people’s eye health. AOA’s 2022 Gamer Survey results revealed, the average gamer spends more than 8 hours a day on screens and has experienced various eye-related symptoms from gaming, including eye strain, headaches, dry eyes, and blurred vision. Further, many gamers are aware of the eye health implications for long-term screen time usage, but less than half (46%) visit a health care professional for a comprehensive eye exam every year. In-person eye exams by doctors of optometry are critical to identify vision and health issues as well as early signs of systemic diseases, such as diabetes, hypertension, autoimmune diseases, and cancers. As part of this year’s Eye Deserve More campaign, AOA is collaborating with optometrist Dr. Jason Compton, AOA member and gamer himself to encourage people to practice healthier screen time habits and be mindful of symptoms such as dry eyes and headaches. “It’s my job as an optometrist to get to know my patients’ habits and behaviors to create tailored recommendations to keep their eyes and overall body healthy, especially since comprehensive eye health is not a one-size-fits-all approach,” says Dr. Compton. “Whether you’re a pro gamer, Twitch streamer, casual scroller, or someone who spends all day working at the computer – it’s critical to see a doctor of optometry in person every year and adapt healthy gaming and screen time habits, like taking regular screen breaks and stopping any gaming activity at least one hour before bedtime.” To find Eye Health Guidance for Screen Time and to book an appointment with a local AOA doctor of optometry, visit AOA.org/EyeDeserveMore. About The American Optometric Association (AOA) The American Optometric Association (AOA) is the leading authority on and advocate for quality eye health care, representing more than 44,000 doctors of optometry, optometry students and optometric professionals. As the sole primary eye care provider in many communities across America, doctors of optometry are often a patient's first entry point into the health care system, and have extensive, ongoing training to examine, diagnose, treat and manage disorders, diseases, and injuries that affect the eye and visual system. Through a nationwide public health initiative, AOA's Eye Deserve More campaign is fostering awareness of the importance of eye health and vision care and the overall health benefits of in-person, comprehensive eye examinations with AOA doctors of optometry for all Americans. References: 1. Entertainment Software Association. February 2022. “2021 Essential Facts About the Video Game Industry.” https://www.theesa.com/resource/2021-essential-facts-about-the-video-game-industry/ Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 22, 2022 12:00 PM Eastern Daylight Time

Advanced AI Drug Development Platform 'DeepMatcher®' 2.0 Launches Worldwide (226330.KQ)

Syntekabio, Inc.

SyntekaBio (226330.KQ)(226330:KS), an AI drug discovery and development company, announced the successful completion of its DeepMatcher® 2.0 performance verification. The advanced version of an AI small molecule drug discovery technology is ready to launch in the global market. The company opened its regional U.S. office in New York City in August. SyntekaBio has developed and verified DeepMatcher® into a three-step process: 1D/2D/3D virtual pre-screening (DMC-PRE), screening by best binding pose and binding energy prediction (DMC-SCR), and molecular dynamics-based self-verification (DMC-MD), which has utilized 1 billion compounds and 600 target models. In silico validation performed on these three modules has authenticated 85-95 percent accuracy, a competitive level in sensitivity and specificity. DeepMatcher® ’s performance is greatly enhanced by the DMC-MD process, in which the molecular dynamic simulation process in the final stage proves to significantly reduce the false positive results that commonly occur and lead to misinterpretation when predicting new drug candidates. The molecular dynamics simulation process typically requires vast computational resources to generate highly accurate results in the screening process. SyntekaBio’s own supercomputing infrastructure is capable of fully supporting the simulation, a major advantage over its competitors. Thus far, the outcome of the screening process evidently points towards the future where it can be applied to the discovery of ‘Molecular Glue’ that can promote and stabilize PPI (Protein-Protein Interaction) between ubiquitin ligase and its target protein. SyntekaBio has also completed the validation of a large-scale drug repurposing project that has been ongoing since the third quarter of 2021. This project was conducted using DeepMatcher® to derive a previously unknown drug-target combination by predicting the binding force between approximately 3,000 drugs and 400 target proteins. By validating approximately 6,000 combinations from the project with in vitro binding efficacy tests, SyntekaBio was able to secure a new effective drug group from a total of 120 protein groups, including the Kinase family, GPRC, Methyltransferase, Deacetylase and Phosphodiesterase. Therefore, the efficacy of DeepMatcher® is positively verified, providing the basis for pipeline development for various disease groups. “We are thrilled to confirm encouraging results from a long-awaited outcome of DeepMatcher® version 2.0 experimentation. SyntekaBio is preparing to launch our AI drug cloud PaaS (Platform as a Service) system based on DeepMatcher® 2.0. We look forward to sharing our cutting-edge technology to enhance drug discovery and development capabilities in the U.S. and internationally,” said SyntekaBio CEO Jongsun Jung, Ph.D. The drug group discovered through SyntekaBio’s large-scale drug repurposing project is undergoing cell experiments in various fields such as anti-cancer, anti-inflammatory, hair loss prevention and growth, and central nervous system diseases. For business development meetings and information about SyntekaBio’s products and services, contact the New York office at +1 (212) 371-2544 or admin.usa@syntekabio.com. Syntekabio is a global artificial intelligence (AI) and big data-based drug discovery and development company, headquartered in South Korea since 2009, with its U.S. operations bringing innovative technologies and science to create transformative medicines worldwide that are compliant with international standards to cure diseases and improve people's lives. Find out more about DeepMatcher®, NEO-ARS™, NGS-ARS™ and PGM-ARS™ at www.syntekabio.com. Contact Details SyntekaBio USA | WMSG Sabina Lee +1 201-402-1400 wgroup@wmedical.org

September 21, 2022 10:07 AM Eastern Daylight Time

Aqua Cultured Foods Unveils Alt-Seafood Dumpling Fillings for Asian Food Go-to-Market Partners

AquaCultured Foods

Food tech startup Aqua Cultured Foods today announced it has developed a minced dumpling filling for its future go-to-market partners specializing in Asian foods including retail and foodservice distributors. One filling option uses Aqua’s alternative shrimp in a bulk, unseasoned format for partners to customize their preparations, which then can be packaged and co-branded. Whether they’re called mandu, jiaozi, or gyoza, dumplings are a dietary staple in countries like South Korea, China and Japan—as beloved as burgers are to North Americans. The global market for frozen dumplings was $5.825 billion U.S. in 2020, and is expected to rise to more than $10 billion by the end of 2027. Traditionally dumplings may be filled with meats, seafood, tofu, and/or vegetables. While Aqua’s R&D focus has been on whole-muscle cut, sushi-quality filets with the same visual appeal of high-grade fish, dumplings can use off-cuts, trims and less than visually perfect filets for minced fillings. Achieving the proper size and texture for filling can also be done economically at scale in large batches, and requires less fermentation time. “We’re glad our partners challenged us to work on dumplings, and lucky to have their guidance through the process of perfecting the taste and filling for Asian palates,” said Aqua chief growth officer Brittany Chibe. “I’m especially happy that this product moves us closer to zero-waste by finding use for our off-cuts, with the added bonus that it’s very efficient to make in volumes appropriate for foodservice.” Interest around Aqua’s minced fillings is not limited to dumplings, nor to shrimp. Other alt-seafood varieties are likely to follow for applications including spicy tuna sushi rolls, seafood cakes/patties, ravioli and cannelloni, and others. Aqua is developing mycoprotein-based calamari, shrimp, scallops, and filets of animal-free tuna and whitefish with a realistic taste and texture. Aqua’s fermentation methods do not use any animal inputs, genetic altering or modification, and can be marketed as non-GMO. Unlike plant-based processed foods formulated with starches and protein isolates, Aqua’s alt-seafood retains its naturally occurring fiber, protein, and other micronutrients. Aqua has recently showcased its alt-seafood for current and prospective partners representing Europe, Asia, and North America. Public tasting events will gauge consumer acceptance later this year with select restaurant partners, followed by in-market product introductions via strategic partners in 2023. ‎About Aqua Cultured Foods Aqua Cultured Foods is an innovative food technology startup developing the world’s first whole-muscle cut seafood alternatives created through microbial fermentation. Its novel technology produces a sustainable, complete protein source using only a fraction of the resources required by traditional aquaculture. As an R&D company with a focus on product commercialization, Aqua Cultured Foods occupies a unique position in the burgeoning alt-seafood market as well as within the fermentation industry. The company’s mission is to mitigate global challenges such as overfishing, climate change and feeding the world’s expanding population with delicious, nutrient-rich foods. Investors include Supply Change Capital, Aera VC, HPA, Sustainable Food Ventures, Hanfield Venture Partners, Lifely VC, Conscience VC, Kingfisher Capital, Big Idea Ventures, and Gonzalo Ramirez Martiarena. For more information visit https://www.aquaculturedfoods.com. Contact Details Evolotus PR Gary Smith +1 818-783-0569 gary@evolotuspr.com Company Website https://www.aquaculturedfoods.com

September 21, 2022 08:38 AM Eastern Daylight Time

Image

Under The Hood Of Options Chain Implications — Understanding How Options Data Can Help Inform Investment Decisions

Protalix BioTherapeautics Inc.

As many investors are aware, options market data can provide some critical insight into future price movements of underlying common stock. It’s often possible to tell how the broader market perceives a company by looking at how options traders are trading it. As a refresher: A "call" or call option is a right to buy an asset at a predetermined price. If traders are buying more puts than calls, it indicates that they expect the price of the underlying security to go down. If they are buying more calls than puts, it suggests that they see a bull market ahead for the security. But options data alone is typically not enough, and it’s always important to conduct one’s own fundamental analysis; for instance, in the pharmaceuticals industry, one could look at factors like upcoming biologics license applications (BLA) - these are usually submitted by companies developing vaccines and other allergenic drug products, blood products, and cellular and genetic therapies. As an example, recent options data points could be helpful in understanding how traders feel about what the future may hold for Protalix BioTherapeutics Inc. (NYSE: PLX). This Israel-based pharmaceutical company focuses on developing, producing, and commercializing recombinant therapeutic proteins produced through its proprietary ProCellEx ® plant cell-based protein expression system. Momentum Toward Finding A Cure For Fabry? Protalix received good news recently from its trial evaluation of the safety and efficacy of its Fabry disease drug compared to benchmark drug agalsidase beta (as part of what is referred to as the BALANCE trial). The study supported Protalix’s efforts to combat Fabry disease, which affects the heart, kidneys, brain, central nervous system, and skin. It is an inherited condition passed from parent to child and is sometimes called Anderson-Fabry disease. Companies currently working on developing gene therapies for Fabry disease include Avrobio Inc. (NASDAQ: AVRO), Freeline Therapeutics Holdings PLC (NASDAQ: FRLN), and Sangamo Therapeutics Inc. (NASDAQ: SGMO). Protalix Positive About Its Q2 Performance Encouraged by the results of their trial, Protalix and its partner Chiesi Global Rare Diseases have announced new topline data from the study. Because the BALANCE trial met its primary endpoint and the drug showed favorable tolerability and immunogenicity profile, Protalix says it will be included in its planned BLA application to the Food and Drug Administration (FDA) by the end of 2022. A BLA is a request to distribute a biologic across states. It is usually submitted after an investigational new drug or an investigational device exemption and after the appropriate studies have been conducted. A biologics license application generally applies to vaccines, allergenic drug products, blood products, and cellular and genetic therapies. Resubmissions of BLA applications are made to answer any company deficiencies that need to be addressed by the applicant before approval. The recent study results are one of the positive momentum examples pointed out by Protalix at the end of the second quarter of 2022, including a 36% increase in revenue to $8.8 million over results from the second quarter of 2021 and license revenue and research and development services up 69% to $5.4 million. A look at the options market data for Protalix could help investors understand how the broader market sees these factors impacting the company’s stock. Traders who are unfamiliar with the complexity of options may want to take the dive into learning more to help round out indicators, especially for individual tickers like PLX — and even traders that are already used to observing the options chain, bid/ask spread, implied volatility, and more may want to take a deeper look at the implications of what the market is saying, such as expectations on clinical trials, financial results, and what the future may look like. For more information on Protalix BioTherapeutics, visit www.protalix.com. Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α–Galactosidase–A protein for the treatment of Fabry disease; alidornase alfa or PRX–110, for the treatment of various human respiratory diseases or conditions; PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Chuck Padala, Managing Director- LifeSci Advisors +1 646-627-8390 chuck@lifesciadvisors.com Company Website https://protalix.com/

September 21, 2022 08:00 AM Eastern Daylight Time

Understanding Hearing Loss: Don’t Miss Out on Hearing the Moments that Matter Most

YourUpdateTV

Untreated hearing loss not only disconnects you from family, friends, and work, it exposes you to higher risk of dementia, depression, memory loss, injury, and cognitive decline. Recently, licensed audiologist, Dr. Cliff Olson, conducted a satellite media tour to talk about hearing loss and the importance of addressing it from a trusted healthcare professional. A video accompanying this announcement is available at: https://youtu.be/xgXK9jvhssc Hearing loss is a major health issue, around the world and in the U.S. The National Institute on Deafness and Other Communication Disorders estimates that 1 in 8 Americans aged 12 or older — about 30 million people — has lost some hearing in both ears. While men are almost twice as likely as women to having hearing loss, it is an issue that is often unaddressed or undertreated by many. In fact, according to the National Institutes of Health, ~ 37.5 million adults report some trouble hearing and an estimated 28.8 million U.S. adults with mild to severe hearing loss could benefit from hearing aids. Too often, people delay seeking care. There are several reasons individuals may delay addressing hearing loss, including: Recognizing and accepting that one may have hearing loss Typical symptoms of hearing loss include having trouble hearing people on the phone, turning up the TV volume, becoming tired from listening and hearing and being able to understand conversations when there’s background noise. Access to HCPs, and misperceptions associated with hearing aids. Hearing aids have evolved so much, so the good news is that: Hearing aids are totally different now with new and improved tech features. Users are getting younger…with average purchase age dropping from 68 to 60. The time people are waiting to purchase hearing aids has dropped to 4 years…not the 6 or 7 years it used to take. Users rarely or never feel embarrassed they wear hearing aids. That’s because they look so cool and do so many great things to connect you to your world. In fact, user satisfaction with hearing aids has increased significantly in the past 20+ years…from 58% to 83%. Hearing speech in noisy environments is still a challenge for people with hearing loss. In fact, 80% of people who wear hearing aids describe hearing in noise as a key challenge. (MarketTrak 2019) The newest hearing aid from GN, ReSound OMNIA, addresses the No.1 hearing aid challenge – hearing speech in noise. ReSound OMNIA allows people to hear and connect with the world naturally, thanks to an outstanding 150% improvement in speech understanding. Go to ReSound.com for a free hearing screening and additional resources for understanding hearing loss and helping family members who are also struggling with hearing loss. About Dr. Cliff Olson Dr. Cliff Olson, from Phoenix, Arizona, USA, is a Doctor of Audiology, advocate for better hearing and creator of popular YouTube channel, Dr Cliff Aud - Doctor Cliff, AuD - YouTube - where he posts educational information about hearing care and hearing aids. The channel has 220k subscribers and has received over 34 million views. Dr. Olson is also the founder of Hearing Up – www.hearingup.com - a network where people can get connected to local experienced hearing professionals who are committed to best practices. A Board-Certified Audiologist, Dr. Olson holds his doctoral degree from the University of Illinois where he is a lecturer for the Department of Speech & Hearing. He is a member of the Academy of Doctors for Audiology and a Fellow of the American Academy of Audiology. Contact Details YourUpdateTV +1 212-736-2727 yourupdatetv@gmail.com

September 19, 2022 11:33 AM Eastern Daylight Time

Video

NanoViricides Reports Its Novel Monkeypox Antiviral Could Reach Clinical Status Rapidly

NanoViricides, Inc.

Learn More about NanoViricides, Inc. by gaining access to the latest research report As cases of the monkeypox virus continue to grow, the race is on for a way to fight this once-rare disease. Since the first reports of monkeypox infection in the United States started popping up in May, cases have now been reported in all 50 states for a total of over 23,000 new infections. In response to that rapid spread, NanoViricides Inc. (NYSEAMERICAN: NNVC) wants to speed up the timeline on the development of its novel antiviral platform to treat the monkeypox virus. Here’s the company’s plan for bringing its monkeypox drug development platform to clinical trials sooner. NanoViricides’s Rapid Drug Development Program For Monkeypox Antiviral Having already begun drug development of NV-387-T, its monkeypox drug candidate, NanoViricides reports that it’s optimistic it can speed up the process to move the antiviral into human clinical trials quickly. Its reasons for that optimism are twofold. First, the active ingredient tecovirimat has already been approved by the Food and Drug Administration (FDA) as a smallpox treatment. Thanks to the FDA’s recent expanded-access protocol, it’s also already being administered to monkeypox patients in the form of TPOXX, an antiviral infusion manufactured by Catalent Inc. (NYSE: CTLT) and distributed by SIGA Technologies Inc. (NASDAQ: SIGA). Second, NanoViricides is optimistic that it can use preclinical data from its other drug development programs to support its application for NV-387-T. That’s because the novel component in its monkeypox drug candidate is NV-387, the same as that used in NV-CoV-2, the company’s COVID-19 drug candidate. NV-387-T encapsulates the already FDA-approved Tecovirimat (for smallpox) within the belly of the NV-387 polymeric micelles, providing substantial additional benefits. That COVID-19 antiviral (NV-387) has already gone through preclinical development and NanoViricides is already working to initiate clinical trials of the drug candidate, so all of that data could be used to meet the safety and toxicology requirements for an investigational new drug (IND) application of NV-387-T for monkeypox with the FDA. NanoViricides’s NV-387-T Could Offer More Effective, More Practical Monkeypox Treatment The current TPOXX treatment has helped doctors combat the recent monkeypox outbreak, but it also comes with some drawbacks. The formulation is an infusion that takes six hours per dose, making it a time-consuming treatment that must be administered at a hospital. It’s also not safe for patients with severe renal impairment (kidney damage). The NV-387-T drug candidate NanoViricides is developing, on the other hand, it would be a 30-minute injection, and the company is also working on an oral version that would eliminate the need for a hospital visit. TPOXX is available as oral capsules which are used in most cases except for severe hospitalized cases at present. NanoViricides believes NV-387-T oral formulation may have substantial advantages in improving the pharmacokinetics and effectiveness of tecovirimat compared to the current TPOXX oral capsules. By encapsulating the active ingredient (tecovirimat) in NanoViricides’s NV-387 platform, the company hopes to make tecovirimat both more effective and safe for patients with kidney damage. In preclinical studies of the company’s COVID-19 drug candidate, NV-387 encapsulation of remdesivir showed improved pharmacokinetics (how well a drug moves through the body) and pharmacodynamics (how the body responds to the drug) compared to Gilead Sciences Inc. ’s (NASDAQ: GILD) formulation. NanoViricides believes that’s because encapsulation prevents the body from metabolizing the drug so it’s able to remain in the system at higher concentrations for longer periods of time. It’s that improved ability to remain in the body that would potentially decrease the risk of kidney toxicity resulting from rapid metabolizing of the drug. And the stability of NV-387 encapsulation compared to the current TPOXX injectable formulation is expected to help reduce infusion time from six hours to 30 minutes. As the company works to speed up development and move its novel Monkeypox antiviral into human clinical trials quickly, it hopes to be able to offer a safer, more effective treatment to combat this outbreak as soon as possible. About NanoViricides NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a development stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide® class of drug candidates are designed to specifically attack enveloped virus particles and to dismantle them. Our lead drug candidate is NV-HHV-101 with its first indication as dermal topical cream for the treatment of shingles rash. In addition, we are developing a clinical candidate for the treatment of COVID-19 disease caused by SARS-CoV-2 coronavirus. The Company cannot project an exact date for filing an IND for this drug because of its dependence on a number of external collaborators and consultants.The Company is now working on tasks for completing an IND application. The Company is currently pursuing two separate drug candidates for the treatment of COVID-19 patients. NV-CoV-2 is our nanoviricide drug candidate that does not encapsulate Remdesivir. NV-CoV-2-R is our other drug candidate that is made up of NV-CoV-2 with Remdesivir encapsulated in it. The Company believes that since Remdesivir is already US FDA approved, our drug candidate encapsulating Remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.The Company intends to re-engage into an IND application to the US FDA for NV-HHV-101 drug candidate for the treatment of shingles once its COVID-19 project moves into clinical trials, based on resources availability. The NV-HHV-101 program was slowed down because of the effects of recent COVID-19 restrictions, and re-prioritization for COVID-19 drug development work.The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for poxviruses if the initial research is successful. The Company's technology is based on broad, exclusive, sub-licensable, field licenses to drugs developed in these areas from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005. This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. Contact Details NanoViricides, Inc. +1 203-937-6137 info@nanoviricides.com Company Website http://www.nanoviricides.com

September 19, 2022 09:26 AM Eastern Daylight Time

1 ... 171 172 173 174 175 ... 249